Linked Life Data

18064689

Source:http://linkedlifedata.com/resource/pubmed/id/18064689

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-12-12
pubmed:abstractText
To distinguish carcinoma, either adenocarcinoma (ADC) or squamous cell carcinoma (SCC), and malignant mesothelioma (MM) in effusion can be a diagnostic challenge based on morphology alone. This study evaluates the utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in effusions when ADC and SCC of the lung are in the differential diagnosis with MM. A cohort of 43 effusions consisting of lung ADC (N = 10), SCC (N = 15), and MM (N = 18, mostly (16) pleural based), was subjected to immunostains using the above mentioned antibodies. WT-1 was positive in 100% MM, 0% ADC, and 0% SCC cases while p63 was positive in 0% MM, 30% ADC, and 80% SCC cases. Stain for MOC31 was positive in 100% ADC, 67% SCC, and 35% MM cases. Similarly, mesothelin antibody stained 100% ADC, 60% SCC, and 47% MM cases. Antibodies for K903 and CK5/6 stained 100% SCC cases but fewer ADC cases (40 and 10%, respectively). In conclusion, in this cohort of mostly pleural malignant effusion, MM can be identified with positive staining for WT-1 and negative staining for p63. Conversely, negative staining with WT-1 and positive staining for p63 exclude MM. Used as part of an immunostain panel, cytokeratin markers (CK5/6 and K903) are useful in differentiating SCC from ADC when MM is already excluded, and MOC31 might have limited value in differentiating ADC from MM. A negative stain with MOC31 can exclude lung ADC. Mesothelin, on the other hand, is not useful in the differential diagnosis of ADC, SCC, and MM.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
8755-1039
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
20-5
pubmed:dateRevised
2011-10-26
pubmed:meshHeading
pubmed-meshheading:18064689-Adenocarcinoma, pubmed-meshheading:18064689-Aged, pubmed-meshheading:18064689-Antibodies, Monoclonal, pubmed-meshheading:18064689-Carcinoma, Squamous Cell, pubmed-meshheading:18064689-Diagnosis, Differential, pubmed-meshheading:18064689-Female, pubmed-meshheading:18064689-GPI-Linked Proteins, pubmed-meshheading:18064689-Humans, pubmed-meshheading:18064689-Immunohistochemistry, pubmed-meshheading:18064689-Keratin-5, pubmed-meshheading:18064689-Keratin-6, pubmed-meshheading:18064689-Lung Neoplasms, pubmed-meshheading:18064689-Male, pubmed-meshheading:18064689-Membrane Glycoproteins, pubmed-meshheading:18064689-Membrane Proteins, pubmed-meshheading:18064689-Mesothelioma, pubmed-meshheading:18064689-Middle Aged, pubmed-meshheading:18064689-Tumor Markers, Biological, pubmed-meshheading:18064689-WT1 Proteins
pubmed:year
2008
pubmed:articleTitle
Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
pubmed:affiliation
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. robertpu@umich.edu
pubmed:publicationType
Journal Article, Evaluation Studies